Navigation Links
MDA supports Duchenne muscular dystrophy research by University of Nevada School of Medicine
Date:8/22/2012

RENO, Nev. A novel treatment in development at the University of Nevada School of Medicine for the most common form of muscular dystrophy is advancing towards human trials with a $308,000 boost from the Muscular Dystrophy Association.

The grant will be used to expand successful research by Associate Professor of Pharmacology Dean Burkin that has shown his laminin-111 protein therapy prevents the onset of the devastating neuromuscular disease in mouse models.

"The early results for laminin-111 as a therapeutic agent for (Duchenne muscular dystrophy) are really exciting," Sanjay Bidichandani, MDA vice president of research, said. "We are eager to see this research go forward."

Duchenne muscular dystrophy is a lethal genetic disease that affects one in 3,500 newborn boys and is caused by mutations in the gene encoding dystrophin. There is no effective treatment or cure.

At the time of diagnosis, DMD patients usually have developed significant muscle disease. The three-year grant will help determine if Burkin's therapy is effective at preventing or reversing disease progression after onset.

"What we aim to discover now is if this therapy is effective at preventing or reversing disease progression after it has already started," he said. "First we will determine if laminin-111 prevents muscle damage after disease onset, preserves muscle function and improves survival of mouse models of DMD. Second, we will determine if laminin-111 prevents cardiomyopathy in mouse models of DMD.

"Finally, in collaboration with researchers at Texas A&M, we will determine if a human version of the protein prevents muscle disease in other animals afflicted with the disease. Results from these studies will pave the way towards developing human recombinant laminin-111 protein as a novel therapeutic for DMD."

Demonstrating that the human version has efficacy in animals with DMD will move this therapy closer to a Food and Drug Administration investigational drug application and potential human clinical trials.

"This MDA grant is a tremendous help in moving this technology forward," Burkin said. "Patients have been waiting a long time for therapies to come about and I think we're at the cusp of major discoveries. Theoretically, laminin-111 protein therapy should be able to treat all patients with Duchenne muscular dystrophy."

Since laminin-111 is a naturally occurring protein already present in our kidneys and other tissues, Burkin said there is a better likelihood that it would not be rejected by the human body.

A postdoctoral researcher in Burkin's lab, Ryan Wuebbles, also received an $180,000 MDA development grant over three years to investigate if laminin fragments can be therapeutic for the treatment of DMD. Wuebbles plans to test different parts of laminin-111 in cells cultured from animals and people with the disease. The most promising of these will be tested and compared to those generated by the full-length protein.

Burkin's work has been funded by the National Institutes of Health and he has a patent license agreement with a biotech company to develop the laminin technology.

His research has been profiled in the internationally acclaimed Better World Report, the American Journal of Pathology and the Proceedings of the National Academy of Sciences. He co-hosted the Myomatrix 2012 conference in April, which brought together 73 international scientists and clinicians to the University of Nevada, Reno campus to explore and share their latest findings and data on treatment breakthroughs related to congenital muscular dystrophy. The results of the Myomatrix Conference were published in the July issue of Neuromuscular Disorders.

In an article published in June in Science Translational Medicine Burkin summarized the impact of a new protein therapeutic, MG53, for the treatment of Duchenne muscular dystrophy.


'/>"/>
Contact: Mike Wolterbeek
mwolterbeek@unr.edu
University of Nevada, Reno
Source:Eurekalert  

Related biology news :

1. Study jointly led by UCSB researcher supports theory of extraterrestrial impact
2. NOAA science supports New Yorks offshore energy planning
3. Leading childhood asthma group supports federal asthma action plan to reduce disparities
4. New compound holds promise for treating Duchenne MD, other inherited diseases
5. New genetically engineered mice aid understanding of incurable neuromuscular disease
6. Real-life spider men using protein found in venom to develop muscular dystrophy treatment
7. Low oxygen levels may decrease life-saving protein in spinal muscular atrophy
8. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
9. Research reveals first evidence of hunting by prehistoric Ohioans
10. Diabetes Research Institute develops oxygen-generating biomaterial
11. APS issues new policy requiring identification of sex or gender in reporting scientific research
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
MDA supports Duchenne muscular dystrophy research by University of Nevada School of Medicine
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
(Date:4/4/2017)... 2017   EyeLock LLC , a leader of ... States Patent and Trademark Office (USPTO) has issued U.S. ... of an iris image with a face image acquired ... company,s 45 th issued patent. ... given the multi-modal biometric capabilities that have recently come ...
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
Breaking Biology News(10 mins):
(Date:7/20/2017)... Reno, NV (PRWEB) , ... July 20, 2017 ... ... a real solution to make clinical trial sites and study participants truly unified. ... manage regulatory compliant (FDA 21 CFR Part 11) research studies entirely on mobile ...
(Date:7/18/2017)... ... July 18, 2017 , ... Blood centers traditionally see ... the region. Nationally, summer is a struggle for community blood centers as high schools ... San Antonio Chamber of Commerce is teaming up with the South Texas ...
(Date:7/17/2017)... (PRWEB) , ... July 17, ... ... of technology-enabled clinical trial solutions, today announced safety software company AB Cube ... the eHealth Solutions business segment to advance technology innovation across life sciences ...
(Date:7/17/2017)... ... 17, 2017 , ... DuPont Pioneer today announced the launch ... (openinnovation.pioneer.com) dedicated to connecting third-party innovators with DuPont Pioneer scientists is now available ... biologicals and digital solutions. , “DuPont Pioneer is building on its long history ...
Breaking Biology Technology: